Group 1 - ARK Innovation ETF (ARKK) has reached a 52-week high, increasing approximately 92.4% from its 52-week low of $36.85 per share [1] - The ETF focuses on "disruptive innovation," investing in companies involved in DNA technologies, automation, robotics, energy storage, artificial intelligence, and Fintech [1] - Cathie Wood, CEO of Ark Investment Management, has made significant moves by purchasing shares of CRISPR Therapeutics AG and Beam Therapeutics Inc., while selling shares of 908 Devices Inc. and Roku Inc., indicating a bullish stance on gene-editing technologies [2] Group 2 - ARKK shows a weighted alpha of 60.23 and a 20-day volatility of 29.55%, suggesting potential for continued strength and gains for investors [4] - Despite market turbulence, Cathie Wood maintains a positive outlook on the transformative power of emerging technologies [3]

[Music] the uh center of the action of our research of development organization which is the lifeblood of a company like Johnson and Johnson. So here we have about 2500 scientists and researchers that are connected with the rest of our R&D organization. Duatau is chairman and CEO of Johnson and Johnson, one of the largest drug makers in the world.We met with him at his firm's research center to learn how a major pharmaceutical company develops cuttingedge drugs. It started with a smaller campus and graduall ...